Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SendRNA Therapeutic
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Flagship Pioneering
Deal Size : $123.0 million
Deal Type : Series C Financing
Senda Biosciences Announces Close of $123 Million Series C Financing
Details : The proceeds of the financing will be used to drive further development of Senda’s proprietary programmable medicines platform and advance its first programs into clinical testing. Senda is developing a new class of SendRNA™ medicines.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 16, 2022
Lead Product(s) : SendRNA Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Flagship Pioneering
Deal Size : $123.0 million
Deal Type : Series C Financing
Lead Product(s) : Nutritional therapies
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Nestle Health Sciences SA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Senda Biosciences has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 26, 2021
Lead Product(s) : Nutritional therapies
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Nestle Health Sciences SA
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?